Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Venous thromboses and thromboembolism in acute stroke: risk factors, diagnosis, treatment, and prevention

Full Text:


Stroke patients among all patients with somatic diseases are at one of the highest risks for venous thromboembolism (VTE). The proven risk factors for venous thrombosis in stroke are prolonged immobilization, elderly age, obesity, diabetes mellitus, and inherited coagulopathies. If no drug prevention is done, the course of stroke is complicated by deep vein thrombosis (DVT) in 75% of the immobilized patients and pulmonary thromboembolism develops in 20%. At present there are mechanical, pharmacological, and combined DVT prevention strategies that may considerably lower the rate of pulmonary embolism. In stroke patients, the use of low-molecular-weight heparins (LMWH) reduces the
risk of DVT, without increasing the risk of hemorrhagic complications. Novel oral anticoagulants used to treat venous thrombosis and VTE in stroke patients are an equivalent alternative to LMWH therapy. Treatment with novel oral anticoagulants to prevent recurrent VTE is effective and safe and may be continued up to 1–2 years.

About the Authors

Andrei Viktorovich Fonyakin
Neurology Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation

L A Geraskina
Neurology Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation


1. <div><p>Савельев ВС. Флебология. Москва: Медицина; 2001. 657 с. [Savel'ev VS. Flebologiya. Moscow: Meditsina; 2001. 657 p.]</p><p>Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995;274(4):335–7. DOI:</p><p>Dutta TK, Venugopal V. Venous thromboembolism: the intricacies. J Postgrad Med. 2009;55(1):54–66.</p><p>British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58(6):470–83. DOI:</p><p>Ferrari E, Baudouy M, Cerboni P et al. Clinical epidemiology of venous thromboembolic disease. Results of a French Multicentre Registry. Eur Heart J. 1997;18(4):685–91. DOI:</p><p>Kearon C, Salzman EW, Hirsh J. Epidemiology, pathogenesis, and natural history of venous thrombosis. George JN, editor. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2001. P. 1153–77.</p><p>Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5(1):63–73. DOI:</p><p>Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Москва: Медиа Сфера; 2010. 56 с. [Rossiyskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy. Moscow: Media Sfera; 2010. 56 p.]</p><p>The European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attacks 2008. Cerebrovasc Dis. 2008;25(5):457–507. DOI:</p><p>Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4):203–5.</p><p>Гагарина НВ, Синицын ВЕ, Веселова ТН, Терновой СК. Современные методы диагностики тромбоэмболии легочной артерии. Кардиология. 2003;(5):77–81. [Gagarina NV, Sinitsin VE, Veselova TN, Ternovoy SK. Currents methods of diagnosis of pulmonary embolism. Kardiologiya. 2003;(5):77–81.]</p><p>Roy PM, Colombet I, Durieux P et al. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ 2005;331(7511):259. DOI:</p><p>Яковлев ВБ, Яковлева МВ. Тромбоэмболия легочной артерии: патофизиология, диагностика, лечебная тактика. Врачебный консилиум. 2005;7(6):493–9. [Yakovlev VB, Yakovleva MV. Tromboemboliya legochnoy arterii: patofiziologiya, diagnostika, lechebnaya taktika. Vrachebnyy konsilium. 2005;7(6):493–9.]</p><p>Snow V, Qaseem A, Barry P et al.; Joint American Academy of Family Physicians /American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2007;146(6):454–8. DOI:</p><p>Torbicki A, Perrier A, Konstantinides S et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29(18):2276–315. DOI:</p><p>Кириенко АИ, Панченко ЕП, Андрияшкин ВВ. Венозный тромбоз в практике терапевта и хирурга. Москва: Планида; 2012. 336 с. [Kirienko AI, Panchenko EP, Andriyashkin VV. Venoznyy tromboz v praktike terapevta i khirurga. Mosсow: Planida; 2012. 336 p.]</p><p>Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost. 2005;3(6):1187–94. DOI:</p><p>Mazzone C, Chiodo GF, Sandercock P et al. Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database Syst Rev. 2004;(4):CD001922.</p><p>Sandercocik TS, Collins R, Counsell C et al.; International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–81. DOI:</p><p>Alikhan R, Cohen AT, Combe S et al.; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963–8. DOI:</p><p>Leizorovicz A, Cohen AT, Turpie AG et al.; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–9. DOI: Epub 2004 Aug 2.</p><p>Cohen AT, Gallus AS, Lassen MR et al. Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost. 2003;1 (Suppl 1):2046.</p><p>Sherman DG, Albers GW, Bladin C et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomized comparison. Lancet. 2007;369(957):1347–55. DOI:</p><p>Morgenstern LB, Hemphill JC, Becker K et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2010;41(9):2108–29. DOI:</p><p>Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009;361(24):2342–52. DOI:</p><p>Benersachs R, Berkowitz SD, Brenner SD et al.; EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010;363(26):2499–510. DOI:</p><p>Beller HR, Prins MH, Lensin LL et al.; EINSTEIN–PE Investigatiors. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012;366(14):1287–97. DOI:</p><p>Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18. DOI:</p></div><br />

For citation:

Fonyakin A.V., Geraskina L.A. Venous thromboses and thromboembolism in acute stroke: risk factors, diagnosis, treatment, and prevention. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):4-9. (In Russ.)

Views: 1541

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)